Pfizer Inc. is a prominent American multinational pharmaceutical and biotechnology corporation with a rich history dating back to 1849. The company has a long history of pharmaceutical innovation and has played a significant role in the development of various medications. Pfizer is headquartered at The Spiral in Manhattan, New York City. The company emphasizes a relentless pursuit of breakthroughs to positively impact patients' lives. Pfizer has manufacturing sites strategically located around the world to ensure an uninterrupted supply of essential medicines, vaccines, and their components. The facilities are designed to meet high standards for safety and efficacy.
Pfizer is indeed the largest pharmaceutical company in terms of annual revenue. In 2022, Pfizer achieved a historic milestone by surpassing $100 billion in annual revenue, making it the first company in the biopharma history to reach this mark. This exceptional revenue was largely propelled by the significant sales of its COVID-19 products.
Pfizer's revenue in 2022 reached $100.33 billion, marking an all-time high for the company.
The substantial revenue increase was driven by the success of its COVID-19 products, particularly the Comirnaty vaccine and the oral antiviral Paxlovid.
Comirnaty, Pfizer's COVID-19 vaccine developed in partnership with BioNTech, generated sales of $37.8 billion in 2022.
The oral antiviral Paxlovid contributed significantly to Pfizer's revenue, with sales amounting to $18.9 billion.
Despite the remarkable performance in 2022, Pfizer anticipates a decline in COVID-dependent revenues in 2023.
The company projects its revenue for 2023 to be in the range of $67 billion to $71 billion.
Pfizer's outstanding financial performance enabled it to surpass Johnson & Johnson as the industry's No. 1 revenue generator.
Johnson & Johnson, which had held this position for a decade, reported sales of $93.8 billion in 2021 and $94.9 billion in 2022.
Pfizer has not yet announced the pricing for its COVID-19 products, Comirnaty and Paxlovid, once the U.S. transitions to a commercial market.
During an investor event in October, Pfizer mentioned considering a price range between $110 and $130 per dose for these products.
Pfizer is actively pursuing the development of an experimental drug for hemophilia A and B.
The drug, marstacimab, has shown promising results in a pivotal study, meeting the primary goals of reducing bleeding episodes.
Marstacimab takes a different approach compared to traditional infused factor replacement therapies, and it is administered subcutaneously.
Pfizer plans to submit regulatory applications for marstacimab based on the positive study results.
The European Commission has granted conditional marketing authorization for ELREXFIO® (elranatamab), a targeted immunotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM).
ELREXFIO is designed for patients who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
ELREXFIO is a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody (BsAb) immunotherapy.
Pfizer achieved a historic milestone by surpassing $100 billion in annual revenue in 2022, driven by the success of its COVID-19 products, particularly Comirnaty and Paxlovid.
The company reported a 23% revenue increase over 2021, making it the largest pharmaceutical company by revenue.
Pfizer had a net debt of about $20.0 billion at the end of October 2023, with $64.1 billion in debt and $44.2 billion in cash.
Pfizer presented positive results for its experimental sickle cell disease drug, GBT-601, at the annual meeting of the American Society of Hematology.
GBT-601 is an oral drug and serves as a successor to Pfizer's marketed medicine Oxbryta, acquired through the 2022 deal with Global Blood Therapeutics.
Both GBT-601 and Oxbryta work by stabilizing the oxygen-transporting protein hemoglobin to prevent the formation of sickle shapes in red blood cells.
Pfizer acknowledged the FDA approval of BioMarin Pharmaceutical's gene therapy Roctavian for severe hemophilia A in June.
Pfizer also has gene therapy candidates for hemophilia, including fidanacogene elaparvovec for hemophilia B and giroctocogene fitelparvovec for hemophilia A.
The company is scheduled to present four-year Phase 1/2 results for the hemophilia A gene therapy during the ASH meeting.
Copyright © 2008-2026 LookChem.com All rights reserved.
